Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

cash2go 242 posts  |  Last Activity: 8 hours ago Member since: Feb 8, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Reason for down

    by lookiamchinese Jan 26, 2016 2:17 PM
    cash2go cash2go Jan 27, 2016 3:45 PM Flag

    The market was unhappy with the price Servier paid for the drug behind the news. I'm sure Cellectis was unhappy they had let it go so cheaply. The deal was made long before the drug had even been tested in humans. There are multiple other Pharma deals that have already been done and probably just as cheaply.

  • cash2go cash2go Jan 27, 2016 2:50 PM Flag

    When Siga threw their current shareholders under the train with the BK exit proposal I suspect the eventual exit plan from BK will be met with lawsuits? Strongly supportive shareholder support of shareholders on the $15 to 0.50 cent ride by Siga shareholders? Looks like the Courts were the whistleblower when they labeled Siga's action's as done in bad faith.
    I thought the gamble to go bad faith was very obvious in Sept '06. Anyone on board with shares had all the facts in front of them and it took little research to understand it was a roll of the dice that big money lawyers would win the ill-gotten gains.

    Draper,ex-long time Perelman friend was kind of a whistleblower.

  • Reply to

    FTC approval for merger, date?

    by cash2go Jan 27, 2016 4:20 AM
    cash2go cash2go Jan 27, 2016 2:33 PM Flag

    Thanks for the date. Makes the current price more understandable. With Washington wary of the Boots deal eventually leading to a move off shores for tax purposes they need to get this deal done soon or there may be some stiff resistance?
    Though there was some kind of review in the first or second quarter??? I'll dig a little and post if I find anything

  • Sooner the better, think we will be much closer to $9 on that day.

  • Reply to

    Unsecured Creditors (Pharmathene)

    by cash2go Jan 25, 2016 6:28 PM
    cash2go cash2go Jan 26, 2016 2:35 PM Flag

    Saga's future:
    The total value of the U.S. contract is about $463 million, Rose said, including $88.5 million for future deliveries and a bonus payment of more than $100 million if the drug wins approval from the FDA.

    The $100M is no included in the $463M contract plus other milestone payments. Also note that nobody is mentioning a replacement order coming in the next few years.

  • Reply to

    Unsecured Creditors (Pharmathene)

    by cash2go Jan 25, 2016 6:28 PM
    cash2go cash2go Jan 26, 2016 2:20 PM Flag

    If old Siga shareholder are wiped out I hope they at least learn the lesson that "the bad faith boys" showed their true colors in September 2006 and that is why I sold all of my SIGA shares in September 2006. Not wishing any bad for any honest small shareholders that invested while believing Siga's BS.

  • Reply to

    Unsecured Creditors (Pharmathene)

    by cash2go Jan 25, 2016 6:28 PM
    cash2go cash2go Jan 26, 2016 2:15 PM Flag

    Markets can't see past a big red "LEGAL" flag. No traders have a system to find and value in this type of situation so we have few buyers. Insiders can return to buying after legal matters end and cheap shares will not last for long. Again that comes from my wild imagination.
    ROI is what I want and PIP looks to be my kind of stock. Recession proof is also nice.

  • cash2go cash2go Jan 26, 2016 1:59 PM Flag

    The market wants to price in a recession for 2016? Look how hard it is to keep oil above $30, Wall Street knows something while they tell us to buy the dips (buy their shares).

  • Reply to

    Unsecured Creditors (Pharmathene)

    by cash2go Jan 25, 2016 6:28 PM
    cash2go cash2go Jan 26, 2016 1:44 PM Flag

    Remember who Pharmathene is dealing with, bad faith:
    "not simply bad judgment or negligence, but rather…the conscious doing of a wrong because of dishonest purpose or moral obliquity"

    So it's good the courts have given Pharmathene negotiating leverage with the $30,000/day in interest. Feeling secure that Siga wants future milestone payments, future contracts and ability to continue pay out handsome salaries and bonuses I expect Pharmathene gets more than $205M to deal with Siga's management style.

    Remember, I'm making up this fairytale:
    As much cash upfront as possible that leaves Siga with a comfortable cash position to "operate" as usual. Pharmathene gets a $100plusM upfront and special shares that pays a dividend until $120 million has been paid out then reverts to ordinary shares. Market value placed on arrangement? $250M

    Remember Pharmathene is reorganized for minimal cash burn and will exists to pay out dividends over the next couple of years. Pharmathene can not look to own more than half of Siga or NOL's will be compromised.

    Fairytale over and everyone lives a happy life. A second order from BARDA in a few years and life gets even better.

  • cash2go cash2go Jan 26, 2016 12:16 AM Flag

    He killed it when he said that even with the long term care rate increases the policies are still losses. Shareholders lose everything before debt loses one dollar or a policy is not honored. I'm sure it's tradeable but I'm limited to long term holds. Trading is for the go go boys and 90% of them lose money.

    BK, restructure and born again is the easiest path.

  • Reply to

    Unsecured Creditors (Pharmathene)

    by cash2go Jan 25, 2016 6:28 PM
    cash2go cash2go Jan 25, 2016 8:32 PM Flag

    I would be OK with Option 4 and expect a bigger payout from Siga insisting the solutions be worked out so that all benefit fully from their loss carry forwards for tax purposes. $250M total payout to Pharmathene shareholders

    Never forget why the court settlement was "risked" down to $205M, bad faith.

  • Reply to

    Unsecured Creditors (Pharmathene)

    by cash2go Jan 25, 2016 6:28 PM
    cash2go cash2go Jan 25, 2016 6:50 PM Flag

     Option 1: Payment in full in Cash of the balance of the PharmAthene Allowed Claim, plus post-petition interest as specified in the Plan. Option 1 shall only be available if the PharmAthene Final Order provides for a Lump Sum Payment Award

    Option 2: N/A

    Option 3: Delivery to PharmAthene of one hundred percent (100%) of the New Common Stock of the Reorganized Debtor

    Optio 4: Such other treatment as may be mutually agreed to by the Debtor or Reorganized Debtor, as applicable, and PharmAthene.

  • The plan is the product of substantial negotiations between the debtor and the statutory committee of unsecured creditors. The debtor and the statutory committee of unsecured creditors support confirmation of the plan and urge all holders of claims entitled to vote on the plan to vote to accept the plan

    ( vote to accept the plan.}

  • Looks like a recession is coming? Record car sales seems to have sucked off any discretionary spending (from oil) for a while. If Apple is seeing a trending down run for the hills folks

  • Reply to

    Ressesion is coming

    by jasonmooore Jan 25, 2016 11:43 AM
    cash2go cash2go Jan 25, 2016 12:00 PM Flag

    See International Paper, a huge "indicator" stock says things are slowing. Sinking today despite Barron's article over the weekend. Was Barrons trying to help readers out of stock???

  • Reply to

    February 2 Disclosure Statement

    by cash2go Jan 21, 2016 11:34 AM
    cash2go cash2go Jan 24, 2016 2:56 AM Flag

    For U.S. federal income tax purposes, the Debtor estimates that, as of December
    31, 2014, it had approximately $87.4 million of federal net operating loss (“NOL”)
    carryforwards (only about $3 million of which was subject to prior limitations). In addition, the
    Debtor expects that it will generate additional NOLs in the event of an adverse final resolution of
    the PharmAthene Action. The amount of any such NOL carryforwards and other tax attributes,
    and the extent to which any limitations apply, remain subject to audit and adjustment by the IRS.

    (Pharmathene is going to be reasonable and want everyone to benefit as much a possible as settlement negotiations come to an end)

  • Reply to

    The value of Pharmathene's NOL's

    by cash2go Jan 22, 2016 1:05 PM
    cash2go cash2go Jan 23, 2016 1:24 PM Flag

    Accounting?

  • Reply to

    The value of Pharmathene's NOL's

    by cash2go Jan 22, 2016 1:05 PM
    cash2go cash2go Jan 22, 2016 9:11 PM Flag

    Siga is paying $30,000/day to get this right the first time. Pharmathene has cut costs as much as possible so that shareholders benefit to the maximum from this settlement.

    GLTA

  • $156 million

    found on yearly 10-K from last March
    next to last page 24-F (I think), next to last page if you want to actually see the entry

  • Reply to

    February 2 Disclosure Statement

    by cash2go Jan 21, 2016 11:34 AM
    cash2go cash2go Jan 22, 2016 11:28 AM Flag

    You have to apply for FDA approval to get it. Approval on 2 animal model for smallpox likely to based on monkeypox in nonhuman primate and smallpox trial in nonprimate study due to humanitarian considerations. Siga passed both monkeypox (several) times and smallpox trial in a single trial. Siga knows the road to FDA approval to collect the $100M, why delay? Siga would have been less convincing in the Delaware Courts if they had this significant milestone passed with it's sizable payment sitting on the cash pile.

    (Chiremix's CMX-001 failed to protect nonhuman primates from monkeypox, making -246 that much more impressive)

    So, was it foot dragging to keep -246 from already gaining FDA approval and the $100M milestone payment and it thus not be a factor in Delaware Courts?

CRIS
1.29Feb 8 4:00 PMEST